2.2.0.25truefalse40501 - Disclosure - Acquisitions (Narrative) (Details)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Duration_1_1_2010_To_12_31_2010http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse12/31/2009
USD ($)
USD ($) / shares
$As_Of_12_31_2009http://www.sec.gov/CIK0000882095instant2009-12-31T00:00:000001-01-01T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$3falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Marketed Products [Member]
12/31/2010
USD ($)
$As_Of_12_31_2010229http://www.sec.gov/CIK0000882095instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseMarketed Products [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldigild_MarketedProductsMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Marketed Products [Member]
{dei_LegalEntityAxis} : CV Therapeutics, Inc. [Member]
4/15/2009
USD ($)
$As_Of_4_15_20093http://www.sec.gov/CIK0000882095instant2009-04-15T00:00:000001-01-01T00:00:00falsefalseMarketed Products [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldigild_MarketedProductsMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseCV Therapeutics, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CvTherapeuticsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : IPR&D [Member]
{dei_LegalEntityAxis} : CV Therapeutics, Inc. [Member]
10/1/2010 - 12/31/2010
USD ($)
$Duration_10_1_2010_To_12_31_2010http://www.sec.gov/CIK0000882095duration2010-10-01T00:00:002010-12-31T00:00:00falsefalseIPR&D [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldigild_IprAndDMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseCV Therapeutics, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CvTherapeuticsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : IPR&D [Member]
{dei_LegalEntityAxis} : CV Therapeutics, Inc. [Member]
4/15/2009
USD ($)
$As_Of_4_15_20096http://www.sec.gov/CIK0000882095instant2009-04-15T00:00:000001-01-01T00:00:00falsefalseIPR&D [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldigild_IprAndDMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseCV Therapeutics, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CvTherapeuticsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Ranexa [Member]
12/31/2010
USD ($)
$As_Of_12_31_2010230http://www.sec.gov/CIK0000882095instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseRanexa [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldigild_RanexaMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Lexiscan [Member]
12/31/2010
USD ($)
$As_Of_12_31_2010228http://www.sec.gov/CIK0000882095instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseLexiscan [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldigild_LexiscanMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : Navitas Assets, LLC [Member]
5/31/2008
USD ($)
$As_Of_5_31_2008http://www.sec.gov/CIK0000882095instant2008-05-31T00:00:000001-01-01T00:00:00falsefalseNavitas Assets, LLC [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldigild_NavitasAssetsLlcMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10falsefalseUSDtruefalse{us-gaap_BusinessAcquisitionAxis} : GS 9667 [Member]
{dei_LegalEntityAxis} : CV Therapeutics, Inc. [Member]
4/15/2009
USD ($)
$As_Of_4_15_20095http://www.sec.gov/CIK0000882095instant2009-04-15T00:00:000001-01-01T00:00:00falsefalseGS 9667 [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrldigild_GSNineThousandSixHundredSixtySevenMemberus-gaap_BusinessAcquisitionAxisexplicitMemberfalsefalseCV Therapeutics, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CvTherapeuticsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11falsefalsetruefalse{us-gaap_DebtInstrumentAxis} : 2.75% Senior Subordinated Convertible Notes Due 2012 [Member]
{dei_LegalEntityAxis} : CV Therapeutics, Inc. [Member]
4/14/2009 - 4/15/2009
Duration_4_14_2009_To_4_15_200922http://www.sec.gov/CIK0000882095duration2009-04-14T00:00:002009-04-15T00:00:00falsefalse2.75% Senior Subordinated Convertible Notes Due 2012 [Member]us-gaap_DebtInstrumentAxisxbrldihttp://xbrl.org/2006/xbrldigild_TwoPointSevenFivePercentSeniorSubordinatedConvertibleNotesDueTwoThousandTwelveMemberus-gaap_DebtInstrumentAxisexplicitMemberfalsefalseCV Therapeutics, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CvTherapeuticsIncMemberdei_LegalEntityAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli012falsefalsetruefalse{us-gaap_DebtInstrumentAxis} : 3.25% Senior Subordinated Convertible Notes Due 2013 [Member]
{dei_LegalEntityAxis} : CV Therapeutics, Inc. [Member]
4/14/2009 - 4/15/2009
Duration_4_14_2009_To_4_15_20092http://www.sec.gov/CIK0000882095duration2009-04-14T00:00:002009-04-15T00:00:00falsefalse3.25% Senior Subordinated Convertible Notes Due 2013 [Member]us-gaap_DebtInstrumentAxisxbrldihttp://xbrl.org/2006/xbrldigild_ThreePointTwoFivePercentSeniorSubordinatedConvertibleNotesDueTwoZeroOneThreeMemberus-gaap_DebtInstrumentAxisexplicitMemberfalsefalseCV Therapeutics, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CvTherapeuticsIncMemberdei_LegalEntityAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli013falsefalsetruefalse{us-gaap_DebtInstrumentAxis} : 2.0% Senior Subordinated Convertible Debentures Due 2023 [Member]
{dei_LegalEntityAxis} : CV Therapeutics, Inc. [Member]
4/14/2009 - 4/15/2009
Duration_4_14_2009_To_4_15_200923http://www.sec.gov/CIK0000882095duration2009-04-14T00:00:002009-04-15T00:00:00falsefalse2.0% Senior Subordinated Convertible Debentures Due 2023 [Member]us-gaap_DebtInstrumentAxisxbrldihttp://xbrl.org/2006/xbrldigild_TwoPointZeroZeroPercentSubordinatedConvertibleDebenturesTwoZeroTwoThreeMemberus-gaap_DebtInstrumentAxisexplicitMemberfalsefalseCV Therapeutics, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CvTherapeuticsIncMemberdei_LegalEntityAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli014falsefalseUSDtruefalse{dei_LegalEntityAxis} : CGI Pharmaceuticals [Member]
7/7/2010 - 7/8/2010
USD ($)
$Duration_7_7_2010_To_7_8_2010http://www.sec.gov/CIK0000882095duration2010-07-07T00:00:002010-07-08T00:00:00falsefalseCGI Pharmaceuticals [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CgiPharmaceuticalsMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$15falsefalseUSDtruefalse{dei_LegalEntityAxis} : CGI Pharmaceuticals [Member]
6/30/2010
USD ($)
$As_Of_6_30_20102http://www.sec.gov/CIK0000882095instant2010-06-30T00:00:000001-01-01T00:00:00falsefalseCGI Pharmaceuticals [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CgiPharmaceuticalsMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$16falsefalseUSDtruefalse{dei_LegalEntityAxis} : CV Therapeutics, Inc. [Member]
4/14/2009 - 4/15/2009
USD ($)
$Duration_4_14_2009_To_4_15_2009http://www.sec.gov/CIK0000882095duration2009-04-14T00:00:002009-04-15T00:00:00falsefalseCV Therapeutics, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CvTherapeuticsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$17falsefalseUSDtruefalse{dei_LegalEntityAxis} : CV Therapeutics, Inc. [Member]
12/31/2010
USD ($)
$As_Of_12_31_201025http://www.sec.gov/CIK0000882095instant2010-12-31T00:00:000001-01-01T00:00:00falsefalseCV Therapeutics, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_CvTherapeuticsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false0gild_MaximumConsiderationOfAcquisitiongildfalsedebitdurationMaximum consideration of acquisitionfalsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse120000000120000000falsetruefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryMaximum consideration of acquisitionNo authoritative reference available.falsefalse3false0us-gaap_BusinessAcquisitionCostOfAcquiredEntityCashPaidus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15truefalsefalse9100000091000000falsefalsefalsetruefalse16truefalsefalse13800000001380000000falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of cash paid to acquire the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f(1)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
falsefalse4false0us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHighus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse2900000029000000falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryFor contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g
-Clause 3
falsefalse5false0us-gaap_BusinessCombinationConsiderationTransferredus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9truefalsefalse1090000010900000falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse102100000102100000falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse13925580001392558000falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents the acquisition-date fair value of the total consideration transferred which consists of the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 39, 40
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f
falsefalse6false0us-gaap_BusinessAcquisitionContingentConsiderationAtFairValueus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse1110000011100000falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryFair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
falsefalse7false0us-gaap_BusinessAcquisitionPurchasePriceAllocationIntangibleAssetsNotAmortizableus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse138900000138900000falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10truefalsefalse9340000093400000falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse2663000026630000falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will not be amortized. Does not include goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
-Subparagraph b
falsefalse8false0gild_AnnualDiscountRateUsedInDiscountedCashFlowModelgildfalsenainstantAnnual Discount Rate Used In Discounted Cash Flow Modelfalsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truetruefalse0.02120.0212falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsetruefalse4falsetruefalse00falsefalsefalsetruefalse5falsetruefalse00falsefalsefalsetruefalse6falsetruefalse00falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8falsetruefalse00falsefalsefalsetruefalse9falsetruefalse00falsefalsefalsetruefalse10falsetruefalse00falsefalsefalsetruefalse11falsetruefalse00falsefalsefalsetruefalse12falsetruefalse00falsefalsefalsetruefalse13falsetruefalse00falsefalsefalsetruefalse14truetruefalse0.180.18falsefalsefalsetruefalse15falsetruefalse00falsefalsefalsetruefalse16falsetruefalse00falsefalsefalsetruefalse17falsetruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepureAnnual Discount Rate Used In Discounted Cash Flow ModelNo authoritative reference available.falsefalse9false0us-gaap_BusinessAcquisitionPurchasePriceAllocationAmortizableIntangibleAssetsus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3truefalsefalse951200000951200000falsefalsefalsetruefalse4truefalsefalse951200000951200000falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7truefalsefalse688400000688400000falsefalsefalsetruefalse8truefalsefalse262800000262800000falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to an identifiable intangible asset that will be amortized.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph e
falsefalse10false0us-gaap_AssetImpairmentChargesus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse136000000136000000falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5truefalsefalse136000000136000000falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 45, 46, 47
falsefalse11false0us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse2953000029530000falsefalsefalsefalsefalse2truefalsefalse138900000138900000falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetarySum of the carrying amounts (original costs for current and prior period additions adjusted for impairment, if any) as of the balance sheet date of intangible assets, excluding goodwill, having a projected indefinite period of benefit.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph b
falsefalse12false0us-gaap_BusinessAcquisitionEffectiveDateOfAcquisitionus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00<font class="_mt">April 15, 2009</font>April 15, 2009falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseOtherus-types:dateStringItemTypenormalizedstringMonth, date and year when the results of operations of the acquired entity began to be included in the income statement of the combined entity. For disclosure purposes, the effective date of an acquisition equates to the acquisition date, when acquisition date is defined as the date on which the acquirer obtained control of the acquired entity. The effective date of an acquisition may be either earlier or later than the date on which the acquisition agreement was executed (closed).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 10, 11
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 3
-Subparagraph c
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph b
falsefalse13false0us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquiredus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsetruefalse4falsetruefalse00falsefalsefalsetruefalse5falsetruefalse00falsefalsefalsetruefalse6falsetruefalse00falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8falsetruefalse00falsefalsefalsetruefalse9falsetruefalse00falsefalsefalsetruefalse10falsetruefalse00falsefalsefalsetruefalse11falsetruefalse00falsefalsefalsetruefalse12falsetruefalse00falsefalsefalsetruefalse13falsetruefalse00falsefalsefalsetruefalse14falsetruefalse00falsefalsefalsetruefalse15falsetruefalse00falsefalsefalsetruefalse16truetruefalse0.890.89falsefalsefalsetruefalse17falsetruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepurePercentage of voting equity interests acquired in the business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph c
falsefalse14false0us-gaap_BusinessAcquisitionCostOfAcquiredEntityEquityInterestsIssuedAndIssuableus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse1570000015700000falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe acquisition-date fair value of the equity interests of the acquirer, including the number of instruments or interests issued or issuable in consideration for the business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f(4)
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 39
falsefalse15false0us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableBasisForDeterminingValueus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00<p style="margin-top: 0px; text-indent: 4%; margin-bottom: 0px;"><font style="font-family: Times New Roman;" class="_mt" size="2">In accordance with the merger agreement, the number of Gilead stock options and restricted stock units into which assumed CV Therapeutics' stock options and restricted stock units were converted was determined based on an option conversion ratio. This conversion ratio was calculated by taking the per share acquisition price of $20.00 and dividing it by the average closing price of our common stock for the five consecutive trading days immediately preceding (but not including) the closing date of April 17, 2009, which was $46.24 per share. The fair value of stock options assumed was calculated using a Black-Scholes valuation model with the following assumptions: market price of $44.54 per share, which was the closing price of our common stock on the acquisition date; expected term ranging from 0.1 to 5.2 years; risk-free interest rate ranging from 0.1% to 1.7%; expected volatility ranging from 37.4% to 43.2%; and no dividend yield. The fair value of restricted stock units assumed was calculated using the acquisition-date closing price of $44.54 per share for our common stock. </font></p>In accordance with the merger agreement, the number of Gilead stock options and restricted stock units into which assumed CV Therapeutics' stock options andfalsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringBasis for determining value of equity interest issued or issuable to acquire the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph d
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 99-12
falsefalse16false0gild_EstimatedFairValueOfUnvestedStockOptionsAndRestrictedStockUnitsAssumedgildfalsedebitdurationEstimated Fair Value Of Unvested Stock Options And Restricted Stock Units Assumedfalsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse1120000011200000falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryEstimated Fair Value Of Unvested Stock Options And Restricted Stock Units AssumedNo authoritative reference available.falsefalse17false0gild_BusinessCombinationRecognizedDeferredTaxAssetsgildfalsedebitinstantBusiness combination recognized deferred tax assets.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse1265600012656000falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse413816000413816000falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryBusiness combination recognized deferred tax assets.No authoritative reference available.falsefalse18false0gild_BusinessCombinationRecognizedDeferredTaxLiabilitiesgildfalsecreditinstantBusiness Combination Recognized Deferred Tax Liabilitiesfalsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse63130006313000falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse426861000426861000falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryBusiness Combination Recognized Deferred Tax LiabilitiesNo authoritative reference available.falsefalse19false0gild_DeferredTaxLiabilityReducedAsResultOfImpairmentChargesgildfalsedebitinstantDeferred Tax Liability Reduced As Result Of Impairment Charges.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17truefalsefalse4970000049700000falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryDeferred Tax Liability Reduced As Result Of Impairment Charges.No authoritative reference available.falsefalse20false0us-gaap_DeferredTaxAssetsValuationAllowanceus-gaaptruecreditinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse1304000013040000falsefalsefalsefalsefalse2truefalsefalse10780001078000falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse1510000015100000falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe sum of the portions of deferred tax assets as of the balance sheet date for which, based on the weight of available evidence, it is more likely than not will not be realized through future reductions of tax-based income.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 17
-Subparagraph e
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43-49
falsefalse21false0us-gaap_DebtInstrumentInterestRateStatedPercentageus-gaaptruenainstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsetruefalse00falsefalsefalsefalsefalse2falsetruefalse00falsefalsefalsefalsefalse3falsetruefalse00falsefalsefalsetruefalse4falsetruefalse00falsefalsefalsetruefalse5falsetruefalse00falsefalsefalsetruefalse6falsetruefalse00falsefalsefalsetruefalse7falsetruefalse00falsefalsefalsetruefalse8falsetruefalse00falsefalsefalsetruefalse9falsetruefalse00falsefalsefalsetruefalse10falsetruefalse00falsefalsefalsetruefalse11truetruefalse0.02750.0275falsefalsefalsetruefalse12truetruefalse0.03250.0325falsefalsefalsetruefalse13truetruefalse0.020.02falsefalsefalsetruefalse14falsetruefalse00falsefalsefalsetruefalse15falsetruefalse00falsefalsefalsetruefalse16falsetruefalse00falsefalsefalsetruefalse17falsetruefalse00falsefalsefalsetruefalseOtherus-types:percentItemTypepureInterest rate stated in the contractual debt agreement.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
falsefalse22false0us-gaap_DebtInstrumentMaturityDateus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsetruefalsefalse2falsefalsefalse00falsefalsetruefalsefalse3falsefalsefalse00falsefalsetruetruefalse4falsefalsefalse00falsefalsetruetruefalse5falsefalsefalse00falsefalsetruetruefalse6falsefalsefalse00falsefalsetruetruefalse7falsefalsefalse00falsefalsetruetruefalse8falsefalsefalse00falsefalsetruetruefalse9falsefalsefalse00falsefalsetruetruefalse10falsefalsefalse00falsefalsetruetruefalse11falsefalsefalse002012-12-312012-12-31falsefalsetruetruefalse12falsefalsefalse002013-12-312013-12-31falsefalsetruetruefalse13falsefalsefalse002023-12-312023-12-31falsefalsetruetruefalse14falsefalsefalse00falsefalsetruetruefalse15falsefalsefalse00falsefalsetruetruefalse16falsefalsefalse00falsefalsetruetruefalse17falsefalsefalse00falsefalsetruetruefalseOtherxbrli:dateItemTypedateDate when the debt instrument is scheduled to be fully repaid, which may be presented in a variety of ways (year, month and year, day, month and year, quarter, etc.).Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 4
falsefalse23false0us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillAmountus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse7011100070111000falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse341910000341910000falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
-Subparagraph c
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 53
-Subparagraph d
falsefalse24false0us-gaap_BusinessCombinationConsiderationTransferredus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsetruefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9truefalsefalse1090000010900000falsetruefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse102100000102100000falsetruefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16truefalsefalse13925580001392558000falsetruefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents the acquisition-date fair value of the total consideration transferred which consists of the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 39, 40
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph f
falsefalse1723Acquisitions (Narrative) (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruetrue
